Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
62,676.16 -1,890.67 (-2.93%) CMC Crypto 200
1,306.12 -90.42 (-6.47%)
ABBV Jan 2025 95.000 put
| Previous close | 0.5300 |
| Open | 0.5300 |
| Bid | 0.2100 |
| Ask | 0.6000 |
| Strike | 95.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.5300 - 0.5300 |
| Contract range | N/A |
| Volume | |
| Open interest | 2k |
- Yahoo Finance Video
Abbvie stock falls amid growing biosimilar competition
Pharmaceutical giant AbbVie Inc. (ABBV) shares came under pressure as the market closed on Friday, following the disappointing first quarter sales performance of the company's arthritis drug, Humira. The company forecast that Humira's sales could slow further in the face of heightened competition. Yahoo Finance's health reporter Anjalee Khemlani breaks down the details, providing insight into the rise of biosimilars in the market. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance. This post was written by Angel Smith
ZacksAbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.
ZacksPCE/Core PCE Numbers Came In Line With Expectations
PCE/Core PCE Numbers Came In Line With Expectations
